Filipa Lynce, MD

Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.

Filipa Lynce, MD, discusses the FDA approval of atezolizumab plus nab-paclitaxel for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1

Only by the end of my first year of fellowship did I realize that beyond your fellowship experience there is a lot you can gain.